1. ALLA AKTIER
  2. NYHETER
  3. SENZIME

Senzime

Nyheter Senzime Nyheter alla bolag

Senzime secures additional major US hospital contract

Senzime, an industry leader in algorithm-based patient monitoring solutions, announces the contract and first deliveries of TetraGraph systems to one of USA’s leading private healthcare providers and not-for-profit health plans. The Integrated Delivery Network (IDN) serves several million members mainly on the US West Coast.

“We continue to win large hospital evaluations and this IDN contract is another major milestone for Senzime in the US market. We estimate the full installation at this hospital system to reach close to 300 TetraGraph systems when fully deployed. The supply contract is a confirmation of our leading product offering, team, and commitment to patient safety. Senzime is perceived as the trusted, long-term vendor of choice, with the capabilities of effectively implementing and supporting large scale implementations. The first TetraGraph and sensor shipments under this contract have already been made”, comments Philip Siberg, CEO of Senzime.

The TetraGraph is the first portable electromyography (EMG)-based neuromuscular monitor on the market that is clinically validated and meets new clinical guidelines published by ASA (American Society of Anesthesiologists) and ESAIC (European Society of Anaesthesiology and Intensive Care). Since its market introduction in 2019, the TetraGraph has been installed at hundreds of leading hospitals across the globe.
 
The TetraGraph system is used during surgery to monitor the patient’s level of neuromuscular blockade accurately. This helps anaesthesiologists secure the right dose of neuromuscular blocking drugs and indicate when it is safe to allow patients to breathe on their own, and thereby avoid serious complications and increase healthcare efficiency.

For further information, please contact:

Philip Siberg, CEO of Senzime AB
Phone: +46 (0) 707 90 67 34, e-mail: philip.siberg@senzime.com

About Senzime

Senzime is a Swedish medical device company that develops, manufactures, and markets CE- and FDA-cleared patient monitoring systems. Senzime’s employees worldwide are committed to the vision of a world without anesthesia- and respiratory-related complications. The company markets an innovative portfolio of solutions, including the TetraGraph® and ExSpiron® 2Xi for real-time monitoring of neuromuscular and respiratory functions, typically under and after surgery. The goal is to help eliminate in-hospital complications, and radically reduce health care costs related to surgical and high acuity procedures.

Senzime targets a market opportunity valued more than SEK 40 billion per year, and operates with sales teams in the world’s leading markets. The company’s shares are listed on Nasdaq Stockholm Main Market (SEZI). More information is available at senzime.com.

Attachments

Senzime secures additional major US hospital contract

Datum 2023-09-18, kl 08:30
Källa MFN
Bifogade filer
Senzime secures additional major US hospital contract
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 10 000 unika besökare per månad. Vår discord har över 5000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!